scholarly journals Quantitative gait analysis as an objective tool to assess functional outcome of musculoskeletal regenerative therapies in horses and dogs

2019 ◽  
Vol 37 (3) ◽  
pp. 30-31
Author(s):  
Filipe Serra Bragança ◽  
P. René Van Weeren

Musculoskeletal regenerative medicine (RM) aims at restoring components of the musculoskeletal system. Most outcome parameters that are used to judge the efficacy of RM treatments focus on the degree to which the newly generated tissue resembles the native tissue and make use of histological, biochemical, and biomechanical techniques. However, in the end it is the functional outcome that counts, and gait is the functional product of the musculoskeletal system. In human medicine, measurement of function is based on the feedback of patients, mostly in the form of so-called visual analogue scoring (VAS) scales, which are seen as relatively reliable, though still subjective and susceptible to bias. In animals this is not possible, and gait is typically scored through application of semi-quantitative scores, like the American Association of Equine Practitioners (AAEP) scale in the horse. Various techniques to measure gait using parameters describing exerted forces (kinetic parameters) and parameters describing motion in space (kinematic parameters) have been developed over the past decades and in more recent times the use of some of these quantitative techniques has become standard in clinical practice in various places (Serra Bragança et al. 2018). It is expected that this use will rapidly increase further, which will have a profound impact on clinical practice. The current developments have already led to a discussion whether we should redefine lameness in the era of quantitative gait analysis (van Weeren et al. 2017). As an evaluation tool for measuring the functionality of musculoskeletal regenerative techniques, quantitative gait analysis has many advantages as it is an excellent technique for longitudinal monitoring in an objective and unbiased way and for subsequent documenting. In this field, the horse is leading but similar techniques are being developed for the dog. Future developments include the generation of big data sets and their exploitation for the development of pattern recognition techniques based on an artificial intelligence approach.

Author(s):  
A. M. Hardeman ◽  
P. R. Weeren ◽  
F. M. Serra Bragança ◽  
H. Warmerdam ◽  
H. G. J. Bok

2007 ◽  
Vol 26 (3) ◽  
pp. 414-419 ◽  
Author(s):  
John R. Merory ◽  
Joanne E. Wittwer ◽  
Christopher C. Rowe ◽  
Kate E. Webster

1999 ◽  
Vol 20 (9) ◽  
pp. 545-553 ◽  
Author(s):  
Andrew D. Beischer ◽  
James W. Brodsky ◽  
Fabian E. Polio ◽  
Jeffery Peereboom

1995 ◽  
Vol 44 (1) ◽  
pp. 413-416
Author(s):  
Yasuyuki Isobe ◽  
Takeshi Minamizaki ◽  
Makoto Okuno ◽  
Kichizo Yamamoto ◽  
Kiyoo Furuse ◽  
...  

2013 ◽  
Vol 37 ◽  
pp. S3
Author(s):  
A. Castagna ◽  
S. Frittoli ◽  
F. Del Sorbo ◽  
A. Elia ◽  
L. Romito ◽  
...  

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Carolyn A Cronin ◽  
Patricia Langenberg ◽  
Tara M Dutta ◽  
Steven J Kittner

Introduction: ECASS III showed benefit of IV tPA for acute ischemic stroke (AIS) 3-4.5 hr from onset in a select group of patients from Europe, with this extended treatment subsequently recommended by the AHA/ASA. We prospectively enrolled AIS patients treated with IV tPA as this recommendation was being applied in clinical practice, to determine safety and efficacy in a representative cohort from the USA. Methods: Consecutive AIS patients treated with IV tPA at 18 primary stroke centers throughout Maryland were approached and informed consent obtained during hospitalization. Sites ranged from small community hospitals to large academic medical centers. In-hospital and demographic data were obtained from each site’s GWTG database or directly from the medical record. Study personnel blinded to the treatment time window obtained 90 day modified Rankin Scale (mRS) by structured phone interview. Patients were grouped by time to treatment (≤ 3hr vs. 3-4.5hr) and compared for presence of additional exclusion criteria from ECASS III that are not standard practice in the USA for ≤ 3hr (age >80, history of stroke and diabetes, oral anticoagulant treatment, and NIHSS>25). Good functional outcome (mRS 0-1 and 0-2), mortality, and symptomatic intracerebral hemorrhage (sICH) were analyzed. Results: Patients treated 3-4.5hr were somewhat younger (mean age 62.6 vs. 66.6, p=0.06), and had smaller infarcts (median NIHSS 5 vs. 8, p=0.04). There was only partial adherence to the additional ECASS exclusions (Table 1). There were no significant differences by time to treatment in sICH, mortality, or 90 day functional outcome (Table 2). Conclusion: For US patients treated with IV tPA 3-4.5 hr from onset in every day practice, there is no evidence for increased risk or worse outcomes compared to standard treatment up to 3 hr.


Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Roslyn A Taylor ◽  
Matthew D Hammond ◽  
Youxi Ai ◽  
Lauren H Sansing

Introduction: Intracerebral hemorrhage (ICH) results in the activation of microglia, the resident immune cells of the central nervous system. Microglia may polarize into an M1, pro-inflammatory phenotype, or an M2 phenotype associated with repair. CX3CR1 is a chemokine receptor on microglia and monocyte subsets. CX3CR1-null microglia have been shown to have dysregulated inflammation. We hypothesize that CX3CR1-null microglia have a prolonged M1 phenotype, contributing to worse functional outcome after ICH. Methods: ICH was modeled by injection of 20μl of blood into the right striatum. Neurological deficit was quantified using digital gait analysis, cylinder test, and beam walking. Mice were sacrificed 14 days after ICH; brains were harvested for flow cytometry and immunohistochemistry (IHC). C57BL/6 (WT) and CX3CR1 GFP/GFP (CX3CR1-null) mice were irradiated and reconstituted with bone marrow from WT mice carrying the congenic marker CD45.1 to generate bone marrow chimeras (CD45.1WT or CD45.1CX3CR1-null). M1 microglia were identified as expressing MHCII and M2 microglia with CD206. Results: The CD45.1CX3CR1-null mice show worse functional outcome 14 days after ICH by cylinder test (p=0.002), beam walking (p=<0.001) and gait analysis (p=0.02). By flow cytometry, few peripheral leukocytes remain in the brain at 14 days, indicating that F4/80 + and CD11b + cells visualized by IHC are likely microglia, not peripheral macrophages. By IHC, CD45.1 CX3CR1-null mice have significantly more amoeboid F4/80 + MHCII + cells per field (M1 microglia) than CD45.1WT mice (p=0.02). CD45.1 CX3CR1-null mice have significantly fewer CD11b + CD206 + cells per field (M2 microglia) compared to CD45.1WT mice (p=0.04). Conclusions: Our results suggest microglial CX3CR1 signaling is necessary for microglia to transition from M1 to M2 and contribute to recovery after ICH.


Stroke ◽  
2019 ◽  
Vol 50 (9) ◽  
pp. 2500-2506 ◽  
Author(s):  
Frank A. Wollenweber ◽  
Steffen Tiedt ◽  
Anna Alegiani ◽  
Burkhard Alber ◽  
Christopher Bangard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document